Trinity Biotech: Reiterate Financial Guidance & Intend to Achieve About $20 Mln of Annualized Run-Rate Ebitdasoon Annualized Rev of About $75 Mln by Q2 2025
trinity biotech:重申財務指導,並打算在2025年第二季度實現年化運行EBITDA利潤率約2,000萬美元和約7500萬美元的年化營收。
Trinity Biotech: Reiterate Financial Guidance & Intend to Achieve About $20 Mln of Annualized Run-Rate Ebitdasoon Annualized Rev of About $75 Mln by Q2 2025
trinity biotech:重申財務指導,並打算在2025年第二季度實現年化運行EBITDA利潤率約2,000萬美元和約7500萬美元的年化營收。
譯文內容由第三人軟體翻譯。